Vutrisiran in Transthyretin Amyloidosis

Vutrisiran in Transthyretin Amyloidosis

Background: Vutrisiran is an RNA interference therapeutic that has demonstrated efficacy for the treatment of patients with transthyretin amyloidosis (ATTR) with polyneuropathy and cardiomyopathy in the phase 3 HELIOS-A and HELIOS-B studies, respectively. During the initial randomized treatment peri...

Full description

Saved in:
Bibliographic Details
Main Authors: Ronald M. Witteles, MD, Pablo Garcia-Pavia, MD, PhD, Caroline Morbach, MD, Julian D. Gillmore, MD, PhD, Mark S. Taylor, MBBS, PhD, Isabel Conceição, MD, William B. White, MD, Cynthia Kwok, MSPH, Marianne T. Sweetser, MD, PhD, Katherine L. Boyle, MD, David Adams, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:JACC: Advances
Subjects:
cardiomyopathy
polyneuropathy
safety
transthyretin amyloidosis
vutrisiran
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25004910
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items